Last reviewed · How we verify
NCT03669835
The Sublimated Mare Milk Supplement in Hepatitis C
NA trial testing Mare milk supplement in Hepatitis C in 100 participants. Completed in 1 December 2020.
20 September 2019
Quick facts
| Lead sponsor | Asfendiyarov Kazakh National Medical University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 28 March 2018 |
| Primary completion | 20 September 2019 |
| Estimated completion | 1 December 2020 |
| Sites | 1 location across Kazakhstan |
Drugs / interventions tested
- Mare milk supplement
- Standard therapy — full drug profile →
Conditions studied
- Hepatitis C — all drugs for Hepatitis C →
Sponsor
Asfendiyarov Kazakh National Medical University
Who can join
Adults 18 to 65, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial studies the effect of sublimated mare milk supplement on patients with hepatitis C.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03669835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis C
Currently open trials in the same condition.
- NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
- NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
- NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
- NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
- NCT05208697 — Tele-Harm Reduction · NA · active not recruiting
Other Asfendiyarov Kazakh National Medical University trials
Trials by the same sponsor.
- NCT06953180 — Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction · recruiting
- NCT06496022 — Comparative Analysis of Risk Factors and Prediction of Frailty Syndrome · active not recruiting
- NCT05970861 — Effect of Natural Food on Gut Microbiome and Phospholipid Spectrum of Immune Cells in COVID-19 Patients · NA · completed
- NCT05095155 — Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Ka · completed
- NCT05090644 — Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on t · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03669835 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asfendiyarov Kazakh National Medical University
- Last refreshed: 8 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03669835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing